Biofrontera (BFRIW) Cash & Equivalents (2020 - 2025)

Biofrontera's Cash & Equivalents history runs 6 years deep, the most recent figure standing at $6.4 million for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 8.38% year-over-year to $6.4 million; the TTM figure through Dec 2025 stood at $6.4 million (up 8.38% YoY), while the FY2025 annual figure was $6.4 million, up 8.38% from the prior year.
• Cash & Equivalents was $6.4 million for Q4 2025 at Biofrontera, up from $3.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $31.9 million in Q2 2022 to a low of $1.3 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $9.8 million across 5 years, with a median of $4.4 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents jumped 1518.71% in 2022, then plunged 94.2% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $24.5 million in 2021, then fell by 29.92% to $17.2 million in 2022, then plunged by 92.19% to $1.3 million in 2023, then surged by 339.69% to $5.9 million in 2024, then rose by 8.38% to $6.4 million in 2025.
• The last three Cash & Equivalents figures came in at $6.4 million (Q4 2025), $3.4 million (Q3 2025), and $7.2 million (Q2 2025), per Business Quant data.